Xcout Intel
Alchemab Therapeutics
Alchemab Therapeutics Ltd is a biotechnology company headquartered in London, England, focused on pioneering patient-centric antibody discovery and development.
Subscribe to see Alchemab Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alchemab Therapeutics at a glance
Alchemab Therapeutics is a biotechnology company headquartered in United Kingdom, founded in 2019. Xcout tracks 4 named people at Alchemab Therapeutics, including Jane Osbourn (Chief Executive Officer). Xcout recorded 1 job posting from Alchemab Therapeutics in the last 90 days.
Alchemab Therapeutics leadership
- Jane OsbournChief Executive Officer
- Dr Ben Porter-BrownChief Medical Officer (CMO)
- Jenna HebertDirector
- Kevin LeeDirector
Hiring at Alchemab Therapeutics
Xcout recorded 1 job posting from Alchemab Therapeutics in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Alchemab Therapeutics's hiring signals →
Alchemab Therapeutics competitors
A few of Alchemab Therapeutics's closest competitors — see the full list of competitors and alternatives →
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Adimab is a biotechnology research company headquartered in Lebanon, New Hampshire, that serves as a biopharmaceutical industry partner for therapeutic antibody discovery and engineering.
Cytospire Therapeutics Limited is a biotechnology research company based in London, United Kingdom. The company is focused on developing a portfolio of next-generation immune cell engagers to improve patients' lives.
IsomAb is a biotechnology research company headquartered in Nottingham, United Kingdom, focused on developing isoform-specific humanized antibodies to treat cardiovascular and other serious diseases.
Get Alchemab Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alchemab Therapeutics in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access